PHASE ONE Foundation

PHASE ONE is thrilled to announce a Medical Grant to Dr. Jennifer Linehan at Saint John's Cancer Institute, Providence Saint John's Health Center to support pioneering research on blood and urine tests for kidney cancer, specifically renal cell carcinoma (RCC). RCC, which makes up 85% of kidney cancer cases, is known for its aggressiveness and tendency to metastasize, making early detection and monitoring crucial. Current imaging techniques often fail to distinguish between cancerous and harmless growths, leading to unnecessary surgeries or delayed treatment. Dr. Linehan's team is developing tests using microRNAs (cfmiRs) as biomarkers, which can be detected in blood and urine, offering a non-invasive diagnostic approach. Read the full grant announcement to learn more about this innovative research with Saint John's Health Center Foundation ?? https://lnkd.in/g45ecwYX

Today’s #FacesofPHASEONE is spotlighting one of our amazing Board Members: Brooke Lande. ? Brooke co-chaired last year's record-breaking Gala with her husband, Ken, and has been a long-time supporter of PHASE ONE. ?? Watch the video ?? to hear about Brooke's connection to PHASE ONE and her passion for ground-breaking cancer clinical trials! ??

Today, on National Caregivers Day, we recognize the family members, friends, and loved ones who dedicate themselves to caring for those facing cancer. Your kindness and compassion make a difference every day. ?? If you're caring for a loved one with cancer, we've gathered a few informational & support resources for you. ?? #1 – Resources for Caregivers from the NCI https://lnkd.in/gMemUBY4 #2 – Caregiving Support Services from Cancer Care https://lnkd.in/eZQcTS5i #3 – Support & Education for Caregivers from Cancer Support Community https://lnkd.in/g_c68nKX

PHASE ONE is thrilled to announce a grant to Dr. Brian Shuch at @UCLA to support a Phase I study investigating a new treatment for Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC). HLRCC is a rare genetic condition that leads to kidney cancer and various debilitating symptoms and is the most common hereditary kidney cancer syndrome, affecting approximately 1 in 2,000 individuals. Current therapies, including immunotherapy and chemotherapy, have shown limited success for HLRCC patients, leading to rapid disease progression and significantly reduced survival rates. Building on promising preclinical research using two FDA-approved drugs, Dr. Shuch will investigate a breakthrough new treatment option for patients. Read the full grant announcement for this groundbreaking study ?? https://lnkd.in/gW2KRswY

Behind every breakthrough in cancer treatment, there’s a researcher dedicated to making it happen. ?? Today, on #WorldCancerDay, we recognize the brilliant minds pushing cancer research forward. Their work is saving lives— one discovery at a time. Join us in funding the future of cancer care ?? https://lnkd.in/grKMbSKs

This January, we’re talking about PREVENTION for Cervical Cancer Awareness Month. ??? HPV causes over 90% of cervical cancer cases—but with the HPV vaccine and regular screenings, most cases can be avoided. Watch the video ?? to learn how HPV leads to cervical cancer, why early detection is critical, and what you can do to protect yourself. For further reading visit: https://lnkd.in/g2f9GQBy #CervicalCancer #CervicalCancerAwareness #CervicalCancerAwarenessMonth

Cheers to another year of advancing life-saving cancer clinical trials. ?? Together, we'll create brighter futures in 2025 and beyond— for our family & yours.

The clock is ticking– only ONE MORE DAY to support cancer clinical trials in 2024! ? By giving before midnight on December 31st, you can: ? Maximize your tax benefits with a year-end gift. ? Fuel life-saving cancer research that transforms hope into action. ? Shape PHASE ONE’s legacy as we celebrate 25 years of progress. Make a donation ?? bit.ly/PO25-donate Your gift today ensures we finish 2024 strong, advancing the best ideas in cancer care and turning promising research into life-saving treatments for families who need them most. Thank you for standing with us this year. Together, we’ll create brighter futures in 2025 and beyond– for our family & yours.

As we near the end of our 25th year, our hearts are filled with immense gratitude for everyone who has helped PHASE ONE become what it is today. ?? Your generosity and steadfast commitment have shaped the future of cancer care—transforming research breakthroughs into life-saving cancer clinical trials, bringing new hope and better options to cancer patients and their families. We couldn’t have done it without you. Thank you!

2024 is PHASE ONE's 25th year– and we have a lot to celebrate! ?? Since 1999, we've funded ground-breaking Phase I + II clinical cancer research in Southern California and beyond– bringing five life-saving drugs to market and many more on the horizon. Watch the video ?? to learn more about the 25 years of PROGRESS you've made possible!